Navigation Links
Insulet Corporation Announces Private Offering of $65 Million of Convertible Senior Notes
Date:6/10/2008

BEDFORD, Mass., June 10 /PRNewswire-FirstCall/ -- Insulet Corporation (the "Company") (Nasdaq: PODD) announced today that it has commenced an offering of $65 million in aggregate principal amount of convertible senior notes due 2013 (the "notes") through an offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended. The Company expects to grant the initial purchasers an option to purchase up to an additional $10 million in aggregate principal amount of notes solely to cover over-allotments, if any.

The notes will be convertible under certain circumstances into cash up to their principal amount and shares of the Company's common stock for the remainder, if any, of the conversion value in excess of such principal amount. The interest rate, conversion rate and other terms of the notes will be determined by negotiations between the Company and initial purchasers of the notes.

The Company will use the net proceeds from the offering to repay and terminate its outstanding term loan and for general corporate purposes.

This notice does not constitute an offer to sell or a solicitation of an offer to buy securities. Any offers of the notes will be made only by means of a private offering memorandum. The notes and any common stock of the Company issuable upon the conversion of the notes have not been registered under the Securities Act of 1933, as amended, or the securities laws of any other jurisdiction and may not be offered or sold absent registration or an applicable exemption from registration requirements.

Forward-Looking Statement

This press release contains forward-looking statements concerning the Company's expectations, anticipations, intentions, belie
'/>"/>

SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Insulet Announces Development Agreement for the First Non-Diabetes Drug Delivery Application for the OmniPod System
2. Insulet Corporation to Present at the Canaccord Adams Diabetes & Obesity Conference on June 6, 2008
3. Insulet Corporation to Present at the Seventh Annual JMP Securities Research Conference on May 20, 2008
4. Insulet Corporation and DexCom Announce Development Agreement
5. Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008
6. Insulet Corporation to Report Third Quarter 2007 Financial Results on Wednesday, November 14th
7. Insulet Corporation Announces Pricing of Secondary Public Offering
8. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
9. ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized Tablets
10. Video: Zix Corporation Issues Statement Supporting Bipartisan Push for Medicare e-Prescribing Requirement
11. Baxa Corporation Named Finalist for Third Year as a Best Company to Work For in Colorado
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)... Plan and Begins Marketing; John Strong, Former Pr...p, Consorta, Inc., to Lead Sales and Marketing Eff...The world,s first permanent international healthca...ess than five years, the key players driving the p...tan tower have been finalized and marketing has be...
(Date:11/20/2008)...nt to lower your risk for type,2 diabetes and hea...g,difference. A study called the Diabetes Prevent...0 percent of your weight can prevent or delay,dis..., 5 percent is just 9,pounds. , In the Uni..., and heart,disease is the leading cause of death...
(Date:11/20/2008)... by HP today announced the winners of its 2008 Vis...th American Exstream User Conference in Cincinnati... (Business Wire EON) November 20, 2008 -- The awa... to make significant strides in improving customer.... Recipients were evaluated on both qualitative an...
(Date:11/20/2008)...wswire/ -- The Gerstman Family was spotlighted on ...rdinary dedication and contribution to physically ...sa Beth Gerstman Foundation. , , Rd.com,s ... those individuals who have made a profound differ...an, co-founder of the Garden City, NY-based Lisa B...
Breaking Medicine News(10 mins):Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 3Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 4Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 5Health News:The 5-Percent Plan: Preventing Diabetes and Heart Disease 2Health News: Exstream Software by HP Announces 2008 Visionary Award Winners : Customers Showcase Innovative Applications Created using the HP Exstream Enterprise Document Automation Solution 2Health News: Exstream Software by HP Announces 2008 Visionary Award Winners : Customers Showcase Innovative Applications Created using the HP Exstream Enterprise Document Automation Solution 3Health News:Gerstman Family Spotlighted on Reader's Digest Website 2
... just seems to be no end to the problems caused by...hat, researchers keep stumbling upon one disease a...ight. // The latest to join the long list is asthm...bes - airways - that carry air in and out of the l...
...alians are leading the world in their obsession fo...tely, this is not a healthy trend, opine researche...tralian and New Zealand Journal of Public Health, ...n for tanning sessions are alarming. This is part...
...s are less likely to quit smoking, say internation...ight up, came about through research involving the...480,125 persons. The study to analyze smoking pat...w Zealand was conducted by Dr. Rachel Huxley of Th...
... a group of mostly older male veterans suffering f.../ an illness that offers a greater susceptibility ... of high dose inhaled corticosteroids (ICS) lowere... The results for this study appear in the first is...
Other Medicine News:Health News:Obesity can Cause Asthma too 2Health News:Sultans of Suntans Warned 2Health News:Asian Smokers in Danger 2Health News:High-dose Inhaled Corticosteroid Use for COPD Could Cut Risk of Lung Cancer 2Health News:High-dose Inhaled Corticosteroid Use for COPD Could Cut Risk of Lung Cancer 3
(Date:11/20/2008)...RK, Nov. 20 Clinical data from a p...th Annual Veith Symposium shows DVT,treatment wit...acchus,Vascular, Inc. (Santa Clara, CA) successfu...about 20 minutes. , This technique, called ...,blood flow more quickly and safely than current ...
(Date:11/20/2008)...OMSO, Norway, November 20 The Scan...pharma has announced results of studies on its,le...CAAC in Washington, DC,the studies showed that t...bacteriocidal effect, significantly better towards...pyogenes than marketed gold standard drugs. In,ad...
(Date:11/19/2008)...ND OAKS, Calif., Nov. 19 ...da Oncology Company, a subsidiary of,Takeda Pharm...nced that,enrollment in the Phase 3 MONET1 trial ...h paclitaxel and carboplatin for the first-line tr...SCLC) has been temporarily suspended,following a ...
(Date:11/19/2008)...de scientists report basic findings on critical en...w to better treat an array of disorders , , ...- Scientists at St. Jude Children,s Research Hosp...ne of the body,s enzyme workhorses called calpains...s, calpains function in many cellular processes, i...
Breaking Medicine Technology:Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Genta Announces Second Quarter 2008 Financial Results and Conference Call 6854 1Genta Announces Second Quarter 2008 Financial Results and Conference Call 6854 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 6854 3Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 6851 1Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 6851 2Cardinal Health Prime Therapeutics Sign Primary Distribution Agreement 6848 1Cardinal Health Prime Therapeutics Sign Primary Distribution Agreement 6848 2Encision Reports First Fiscal Quarter Results 24725 1Encision Reports First Fiscal Quarter Results 24725 2Encision Reports First Fiscal Quarter Results 24725 3Encision Reports First Fiscal Quarter Results 24725 4
...Call/ -- Bristol-Myers,Squibb Company (NYSE: BMY) ... showed that treatment with Baraclude (entecavir),...fovir at 48 weeks,-- a result that was also seen a...rom an open-label, randomized viral kinetics study...en (HBeAg),positive patients were presented at the...
.../ -- Data presented,today at a major medical meeti...ts administered once-daily for five days is as,eff...00 mg) for 10,days for the treatment of complicate...ephritis (AP). , Ortho-McNeil, Inc., the company t...ta during a scientific session at the annual,meeti...
Other Medicine Technology:Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4
This electronic survival guide provides all the essential information that every surgery intern needs from Day 1 on the wards.
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan
CURRENT Consult: Surgery brings you authoritative clinical answers on more than 360 surgically treated disorders in the most efficient format, perfectly devised for the busy physician.
Taber's Cyclopedic Medical Dictionary has definitions and information they need to provide care for their patients.
Medicine Products: